Voya Investment Management LLC Sells 96,398 Shares of Avanos Medical, Inc. $AVNS

by · The Cerbat Gem

Voya Investment Management LLC decreased its position in Avanos Medical, Inc. (NYSE:AVNS – Free Report) by 41.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 138,233 shares of the company’s stock after selling 96,398 shares during the period. Voya Investment Management LLC’s holdings in Avanos Medical were worth $1,598,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after purchasing an additional 2,307 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after buying an additional 5,083 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Avanos Medical during the second quarter valued at $126,000. State of Wyoming raised its holdings in shares of Avanos Medical by 104.6% in the first quarter. State of Wyoming now owns 10,508 shares of the company’s stock valued at $151,000 after acquiring an additional 5,371 shares in the last quarter. Finally, Diametric Capital LP purchased a new stake in Avanos Medical in the second quarter worth about $156,000. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Avanos Medical Price Performance

AVNS opened at $11.33 on Tuesday. The firm has a market capitalization of $525.94 million, a PE ratio of -1.11 and a beta of 1.09. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. The business’s 50-day moving average is $11.49 and its two-hundred day moving average is $11.64. Avanos Medical, Inc. has a 1 year low of $9.30 and a 1 year high of $17.69.

Avanos Medical (NYSE:AVNS – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The business had revenue of $177.80 million for the quarter, compared to analysts’ expectations of $164.50 million. During the same period last year, the business earned $0.33 EPS. The company’s revenue was up 4.3% compared to the same quarter last year. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Research analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AVNS. Zacks Research cut shares of Avanos Medical from a “hold” rating to a “strong sell” rating in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Finally, Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Two research analysts have rated the stock with a Sell rating, According to MarketBeat.com, Avanos Medical currently has a consensus rating of “Sell”.

Check Out Our Latest Report on Avanos Medical

Insider Buying and Selling

In other Avanos Medical news, SVP Kerr Holbrook sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total value of $165,000.00. Following the completion of the sale, the senior vice president directly owned 83,860 shares in the company, valued at $922,460. This trade represents a 15.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.64% of the stock is owned by insiders.

About Avanos Medical

(Free Report)

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

Read More

Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical, Inc. (NYSE:AVNS – Free Report).